Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

GLP-1 receptor agonists such as the popular weight loss/diabetes therapies Mounjaro, developed by Eli Lilly (NYSE:LLY), and ...

In the wake of weight-loss drugs and the rising importance of health, the iconic cultural brand must double down on its roots ...

GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly ...

CheqUp said it had experienced a spike in interest from consumers wanting to switch or begin taking the medication.

This is all you need to know about the new weight loss jab 'Reta' that's said to be 3 times stronger than Ozempic.

Dr. Hussein Tawbi, who works for MD Anderson in Houston, said there are two things he hopes people take away from the story of Cowboys owner Jerry Jones beating cancer.

Viking Therapeutics (VKTX 5.71%) fell a whopping 39.2% from their previous close on Tuesday, Aug. 19. Investors were reacting ...

A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits ...

Its amazing results have been hailed by Jeremy Clarkson, Whoopi Goldberg and The Telegraph’s own Allison Pearson, but from next month, the popular weight-loss drug Mounjaro could become inaccessible ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...